Opendata, web and dolomites

BiomStrip SIGNED

Over-The-Counter Test Strip for Early-Stage Cancer Screening

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BiomStrip project word cloud

Explore the words cloud of the BiomStrip project. It provides you a very rough idea of what is the project "BiomStrip" about.

engineer    form    breakthrough    business    solution    onset    overheads    offers    flora    invasive    super    ipr    capacity    survival    gut    ultimately    alleviating    tests    validation    successfully    detection    screening    covered    introduces    diseases    suffers    healthcare    vital    trl6    grown    bought    gradually    disruptive    costly    partnership    strategic    pathophysiological    biomarker    fastest    selectively    burdens    sme    intensity    vastly    causing    breast    multinational    scalability    pioneering    drops    therapeutical    spread    keeping    disease    point    difficult    diagnostic    indicator    carry    empowering    handled    commercialisation    building    pregnancy    types    diagnostics    platform    feasibility    markets    designed    dysbiosis    biomstrip    sensitive    detecting    histological    drastically    stage    effort    companies    diagnosed    therapy    time    compliance    highest    explosive    once    sums    effectiveness    globally    death    market    rate    device    detect    risk    workplan    subsequently    counter    tech    microbial    options    granting    model    spent    cancer    license    accurate    deaths    strategies    sensitivity    transform    entry    fashion    patients    preventive    resource    plan    minimised   

Project "BiomStrip" data sheet

The following table provides information about the project.

Coordinator
LOGODERM OKTATO ES SZOLGALTATO KORLATOLT FELELOSSEGU TARSASAG 

Organization address
address: GARDONYI GEZA UTCA 39
city: DEBRECEN
postcode: 4032
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Hungary [HU]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-07-01   to  2019-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LOGODERM OKTATO ES SZOLGALTATO KORLATOLT FELELOSSEGU TARSASAG HU (DEBRECEN) coordinator 50˙000.00

Map

 Project objective

Cancer is the second leading cause of death globally, causing 1 in 6 deaths. If cancer is diagnosed at early stage, it is highly likely to be treated successfully. Once it has grown and spread, therapy is vastly more difficult and costly, and survival rate drops rapidly. Screening is a vital healthcare element for early detection but suffers from burdens of cost, capacity, compliance, and detection sensitivity problems. BiomStrip introduces a pioneering screening solution that can carry out cancer screening in the fashion of the common pregnancy tests. Building on our recent breakthrough results in biomarker validation granting TRL6 stage, we have designed a diagnostic device that is low-cost, non-invasive, accurate, can be handled by consumer, and bought over-the counter. The diagnostic method is based on detecting dysbiosis of gut microbial flora, a highly sensitive indicator of pathophysiological processes able to selectively show disease onset at super-early stage, even before histological changes are observable. The method is ultimately able to detect most cancer types and even other diseases, making it a future platform technology. For highest scalability, fastest time-to-market, explosive growth, low resource-intensity, and minimised risk and overheads, we will license production and commercialisation to established multinational companies, keeping our focus as high-tech SME. Breast cancer will be our market entry point and other diseases will be covered subsequently form own resources. To engineer this Workplan, a feasibility study will assess entry use cases and their markets, analyse business model and partnership options, and evaluate IPR strategies in a Strategic Business Plan. The disruptive approach offers to transform cancer screening from top-down to bottom-up: empowering patients, gradually alleviating healthcare systems large effort and sums spent on preventive cancer diagnostics, and drastically improving therapeutical effectiveness.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BIOMSTRIP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BIOMSTRIP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

BeatsDigTherapeutics (2019)

Project SCALE: Tailored Digital Therapeutics for Neurological and Brain Disorders

Read More  

COUNTMITMENT (2019)

NATURAL CAPITAL ACCOUNTANCY TO IMPROVE REPORTING AND ENVIRONMENTAL PERFORMANCE

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More